Shattuck Labs (STTK) Non Operating Income (2019 - 2026)
Shattuck Labs' (STTK) quarterly Non Operating Income came in at $778000.0 in Q1 2026, up 13.25% year-on-year from $687000.0 in Q1 2025, and up 13.25% on a QoQ basis from $687000.0 in Q1 2025.
Shattuck Labs (STTK) Non Operating Income (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has 5 years of Non Operating Income data on file, last reported at $778000.0 in Q1 2026.
- On a quarterly basis, Non Operating Income rose 13.25% year-over-year to $778000.0 in Q1 2026; TTM through Mar 2026 was $236000.0, a 36.56% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 47.66% from the prior year.
- Non Operating Income for Q1 2026 stood at $778000.0, up from $687000.0 in the prior quarter.
- Over the last five years, Non Operating Income for STTK reached as high as $778000.0 in Q1 2026 and fell as low as $687000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Shattuck Labs | 795.74 Mn | 795.74 Mn | - | 778,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 778,000.00 |
| Mar 31, 2025 | 687,000.00 |
| Dec 31, 2021 | -1.40 Mn |
| Sep 30, 2021 | 170,000.00 |
| Jun 30, 2021 | 914,000.00 |
| Mar 31, 2021 | 610,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 10,000.00 |
| Jun 30, 2020 | 112,000.00 |
| Mar 31, 2020 | 207,000.00 |
| Dec 31, 2019 | 255,000.00 |
| Sep 30, 2019 | 248,000.00 |